Abstract:Rationale and Objectives: The classification of patients based on pathology and molecular features is important for improving WHO grade II glioma patient prognosis, especially for the initially diagnosed patients. Less invasive and more convenient methods for the prediction of the pathological type and gene status are desired. Materials and Methods: This study investigates the ability to use conventional magnetic resonance imaging (MRI) and computed tomography (CT) features for determining the Isocitrate Dehydrogenase (IDH)-mutant and 1p/19q-codeletion status, through a retrospective review of information obtained from 189 WHO grade II glioma patients. Diffuse astrocytoma (IDH-mutant), Diffuse astrocytoma (IDH- wildtype) and Oligodendroglioma (IDH-mutant and 1p/19q co-deletion) were included in this cohort. All patients were divided into IDH-mutant group and IDH-wildtype group according to the IDH R132H mutation status. Moreover, all patients were divided into 1p/19q co-deletion group and 1p/19q non-codeletion group according to the 1p and 19q chromosome status. Patients underwent pre-operative CT and MRI scans, followed by operation and histopathological analyses, including immunohistochemistry and polymerase chain reaction analysis for IDH mutants, and fluorescence capillary electrophoresis analysis for the 1p/19q co-deletion. The x2 test, logistical regression and receiver operating characteristic curve analysis were conducted for statistical analysis. Results: IDH-mutant group patients exhibited a higher calcification frequency (25.2% vs 2.4%, p = 0.006) and lower frequency of T1 enhancement (20.4% vs 38.1%, p = 0.028) comparing patients in IDH-wildtype group, while 1p/19q co-deletion group patients exhibited a higher calcification frequency (46.67% vs 2.6%, p < 0.001) and lower homogenous signal frequency in T2WI (12.0% vs 31.6%, p = 0.014), sharp lesion margins (14.7% vs 43.0%, p = 0.010), T2/fluid attenuated inversion recovery mismatch signs (22.7% vs 50.9%, p = 0.001), and subventricular zone involvement (64.0% vs 15.8%, p = 0.021) comparing patients in 1p/19q non-codeletion group. According to the results of receiver operating characteristic analysis, these features were observed to have certain diagnostic abilities, especially with regard to combination parameters, which had a high diagnostic capability, with an area under the curve of 0.848. Conclusion: Conventional MRI and CT features, which still represent the most convenient and widely used predictive method, might be a promising noninvasive predictor for differentiating between varied WHO grade II gliomas. Patients with calcification and T1 nonenhancement are more likely to be IDH-mutant. Moreover, patients with noncalcification, homogenous signal, sharp lesion margins, subventricular zone involvement on T2 and T2/fluid attenuated inversion recovery mismatch signs are more likely to be 1p/19q non-codeletion.

IDH1 Status is Significantly Different Between High-Grade Thalamic and Superficial Gliomas.

[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].

High IDH1 Expression is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

Diagnostic and prognostic value of IDH1 mutation in gliomas

Analysis of Isocitrate Dehydrogenase 1 Mutation in 97 Patients with Glioma

Mutation Analysis Of Idh1 In Paired Gliomas Revealed Idh1 Mutation Was Not Associated With Malignant Progression But Predicted Longer Survival

IDH-1R132H Mutation Status in Diffuse Glioma Patients: Implications for Classification.

Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing

[Correlation Between IDH1 Mutation and Prognosis in Supratentorial High-Grade Astrocytomas].

Predicting IDH mutation status as well as Ki-67 and p53 expression in high-grade gliomas using amide proton transfer-weighted and arterial spin labeling MRI

Isocitrate Dehydrogenase Mutation is Associated with Tumor Location and Magnetic Resonance Imaging Characteristics in Astrocytic Neoplasms.

Expression and Significance of Isocitrate Dehydrogenase 1 Mutation in Human Glioma

Diffuse Isocitrate Dehydrogenase–Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis

GENETIC VARIATION BETWEEN IDH MUTANT AND IDH WILD-TYPE GLIOMA

[Relationship Between IDH1 Mutation and Clinic Pathologic Features in Human Supratentorial WHO Grade II Gliomas].

High-grade Gliomas with Isocitrate Dehydrogenase Wild-Type and 1p/19q Codeleted: Atypical Molecular Phenotype and Current Challenges in Molecular Diagnosis.

Correlation of IDH1/2 Mutation with Clinicopathologic Factors and Prognosis in Anaplastic Gliomas: a Report of 203 Patients from China

The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.

IDH1/2 Gene Hotspot Mutations in Central Nervous System Tumours: Analysis of 922 Chinese Patients

IDH Clonal Heterogeneity Segregates a Subgroup of Non‐1p/19q Codeleted Gliomas with Unfavourable Clinical Outcome

Idh1/Idh2 Mutations Define The Prognosis And Molecular Profiles Of Patients With Gliomas: A Meta-Analysis